---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-044549"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2025-03-25T23:59:59+00:00"
generated_at: "2026-05-24T05:55:35.189386+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Acrivon reports ACR-368 35% ORR in refractory endometrial cancer; deprioritizes ovarian/bladder

## Summary
- Preliminary cash, cash equivalents and ST investments ~$184.6M as of Dec 31, 2024; runway into 2027.
- ACR-368 BM+ endometrial cancer: 35% confirmed ORR, 80% DCR in 20 heavily pretreated patients (median 2 prior lines).
- In BM+ patients refractory to last prior therapy (ORR 0%), ACR-368 achieved 33% ORR and 75% DCR.
- Company deprioritized ovarian and bladder cancers; shifting resources to ACR-368 in endometrial cancer and ACR-2316.
- ACR-2316 Phase 1: cleared DL2 without safety concerns; initial clinical activity observed in a patient at DL3.

## SEC filing metadata
- accession: 0000950170-25-044549
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2025-03-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000095017025044549/0000950170-25-044549-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000095017025044549/acrv-20250325.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-044549
- JSON: https://secwatch.observer/filing/0000950170-25-044549.json
- Plain text: https://secwatch.observer/filing/0000950170-25-044549.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.